A new paradigm for tumor immune escape: β-catenin-driven immune exclusion
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Increasing evidence is emerging that immunotherapeutic interventions, including checkpoint blockade, are predominantly effective in patients with a pre-existing T cell-inflamed tumor microenvironment. Understanding the mechanisms leading to a non-T cell-inflamed microenvironment are crucial for the development of novel treatment modalities to expand the fraction of patients benefiting from immunotherapy. Based on the hypothesis that one source of inter-patient heterogeneity would lie at differential activation of specific oncogene pathways within the tumor cells themselves, our group recently observed that tumor-cell intrinsic activation of the WNT/β-catenin pathway correlates with absence of T cells from the microenvironment in metastatic melanoma. Genetically-engineered mouse models confirmed a causal relationship, via a mechanism of failed Batf3-lineage dendritic cell recruitment. Hence, tumor cell-intrinsic activation of β-catenin is the first oncogenic pathway demonstrated to exclude the anti-tumor immune response, revealing a potential therapeutic target for improving immunotherapy responsiveness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Post-treatment biopsies from melanoma patients receiving anti-PD-1 have revealed an expanded number of proliferating CD8 T cells penetrating deep within the tumor microenvironment [4].”
BackgroundMelanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · cited 1×
“Beginning with the hypothesis that activation of specific oncogene pathways might mediate immune exclusion in tumors from individual patients [6], we utilized metastatic melanoma data from 266 tumor samples from The Cancer Genome Atlas (TCGA) and segregated them based on the presence or absence of a gene signature ind…”
MethodSelf-citationBrafV600E cooperates with Pten loss to induce metastatic melanoma
Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189
Spranger, S., Koblish, H. K., Horton, B., Scherle, P. A., Newton, R., & Gajewski, T. F. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-3 · Cited by 552 · cited 1×
“These data are consistent with preclinical data demonstrating that most of the therapeutic effect of checkpoint blockade can be attributed to reactivation of CD8 T cells already present within the tumor [5].”
ResultSelf-citation
Cited by
Inflammation and cancer: triggers, mechanisms, and consequences
Greten, F. R., & Grivennikov, S. I. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.025 · Cited by 3,806
“…at the single cell level resolution, have been defined to be informative for cancer prognosis, its sensitivity to conventional and immunotherapies and future mechanistic insights (Bindea et al., 2013; Jerby-Arnon et al., 2018; Riaz et al., 2017; Spranger and Gajewski, 2015; Sweis et al., 2016).”
BackgroundWnt/beta-catenin pathway: modulating anticancer immune response
Pai, S. G., Carneiro, B. A., Mota, J. M., Costa, R., Leite, C. A., Barroso-Sousa, R., Kaplan, J. B., Chae, Y. K., & Giles, F. J. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0471-6 · Cited by 703
WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment
Li, X., Xiang, Y., Li, F., Yin, C., Li, B., & Ke, X. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02293 · Cited by 291
WNT Signaling in Tumors: The Way to Evade Drugs and Immunity
Martin-Orozco, E., Sanchez-Fernandez, A., Ortiz-Parra, I., & Ayala-San Nicolas, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02854 · Cited by 286
Chae, Y. K., Chang, S., Ko, T., Anker, J., Agte, S., Iams, W., Choi, W. M., Lee, K., & Cruz, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-21061-1 · Cited by 253
Metadata
- Authors
- Spranger, S., & Gajewski, T. F.
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2015-09-15
- Volume
- 3
- Issue
- 1
- Pages
- 43-43
- ISSN
- 2051-1426 (ISSN-L)
- OpenAlex
- W1856892620
- Cited by
- 139
- References
- 4
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A new paradigm for tumor immune escape: β-catenin-driven immune exclusion. https://app.cochat.ai/papers/10.1186/s40425-015-0089-6
- The paper
- Spranger, S., & Gajewski, T. F. (2015). A new paradigm for tumor immune escape: β-catenin-driven immune exclusion. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-015-0089-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.